rituximab,epcoritamab,lenalidomide
abbvie,genmab
['epcore,nhl,1', 'nhl', 'epcoritamab', 'epcore,fl,1', 'epcore,nhl,2', 'ritux']
congress | #ash22 , presents an update from the phase i/ii epcore nhl-2 trial of epcoritamab with r2 in patients with r/r #fl. the combination showed potent anti-tumor activity and a manageable safety profile with no new safety signals observed 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm